Cordis (medical) division, a cardiology and endovascular device manufacturer, for $1.94 billion. The acquisition was completed on October 4, 2015. Cardinal sold the division in August 2021 to Hellman & Friedman, a private equity firm, for $1 billion. In April 2017, Cardinal Health announced the plan to acquire the patient product portfolio from Medtronic for $6.1 billion. The acquisition was completed on July 30, 2017. Finances For the fiscal year 2020, Cardinal Health reported an annual revenue of $152.9 billion an increase of 5.1% over the previous fiscal cycle. Cardinal Health's shares traded at over $51 per share, and its market capitalization was valued at over US$14.97 billion in August 2021. Controversy Restatements In September 2004, Cardinal Health announced plans to restate past results for fiscal 2001, 2002, 2003, and the first three quarters of 2004 downward, after an accounting review and an ongoing federal investigation. In 2005, in connection with the Audit Committee's conclusions reached in September and October 2004, the company made certain reclassification and restatement adjustments to its fiscal 2004 and prior historical consolidated financial statements. According to The Wall Street Journal, "Analysts called the restatement decision troubling, yet limited in scope." FDA action In August 2006, Cardinal Health ceased production of its Alaris SE infusion pump after approximately 1300 units were seized by the United States Food and Drug Administration (FDA). In February 2007, Cardinal Health signed a consent decree with the FDA which promised procedures to guarantee the safety of the Alaris SE. After FDA inspections, Cardinal Health entered into a further consent agreement with the FDA in 2009. DEA investigation into Oxycodone diversion In 2008, Cardinal Health agreed to pay $34 million in civil penalties to settle DEA allegations that it failed to report suspicious orders of hydrocodone. The fine followed a 10-month DEA suspension of a Lakeland, Florida distribution facility and two others in New Jersey and Washington. On February 2, 2012, the Drug Enforcement Administration again suspended the license of the firm's Lakeland distribution center to distribute controlled substances on charges that it had allowed four Florida pharmacies to purchase excessive amounts of controlled substances, in particular oxycodone. Cardinal Health obtained a restraining order against the suspension, but the suspension was upheld on February 29 by a Federal district court because the court agreed with the DEA that Cardinal Health's activities represented an "imminent danger to the public." The company stated that